Founded 30 years ago, the Molecular Immunology Center (CIM) is one of the main scientific institutions in Cuba, as it has managed to develop important medicines, especially for being one of the leaders in the fight against cancer in the country.
Created by the initiative of the historic leader of the Revolution, Fidel Castro, on December 5, 1994, this institution currently has 21 products in line and 6 are registered, among which is CIMAher (nimotuzumab), a humanized monoclonal antibody against the epidermal growth factor receptor for the treatment of head and neck tumors, malignant glioma (adult and pediatric), esophageal tumors of epithelial origin and pancreatic tumors and CIMAvax-EGF, a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC) in advanced stages.
This institution, in addition to having production facilities in Havana and Santiago de Cuba, has a marketing agency that has established contracts with around 45 companies of about 100 countries and exports its medicines to more than 30 nations.
Among its most recent agreements is the registration of the Cuban vaccine Cimavax by the Ministry of Health of Belarus. There have been numerous achievements of the CIM during the years it has been working in favor of human health, including more than 30 awards granted to the institution by the Cuban Academy of Sciences, evidence of its important contributions to the health system of the country and, therefore, of the world.
I send my warmest congratulations to all its professionals and workers in general for this new anniversary.
CubaPLUS Latinos
CubaPLUS Guyana
CubaPLUS Travel